首页 > 最新文献

Molecular and clinical oncology最新文献

英文 中文
Prognostic value of serum uric acid levels following radiotherapy and chemotherapy in nasopharyngeal carcinoma. 鼻咽癌放化疗后血清尿酸水平的预后价值。
IF 1.4 Q4 ONCOLOGY Pub Date : 2026-01-08 eCollection Date: 2026-02-01 DOI: 10.3892/mco.2026.2924
Xianming He, Qiwei Luo, Yuhao Ding, Jianwu Ding, Ronghuan Hu, Jia-Li Hu, Lei Tao, Jianze Zhang, Zhenxing Huang, Xiaoqiang Chen, Jiayin Wu, Su Deng, Shubin Luo, Lei Zeng, Mengmeng Liu

To evaluate the association between serum uric acid (SUA) levels and prognosis in patients with nasopharyngeal carcinoma (NPC) treated with a comprehensive regimen of induction chemotherapy, intensity-modulated radiation therapy (IMRT), and adjuvant chemotherapy. A total of 182 patients with NPC treated at the Second Affiliated Hospital of Nanchang University between 2017 and 2021 were retrospectively analyzed. SUA levels were recorded at four time points: Pre-treatment, post-induction chemotherapy, post-IMRT and post-adjuvant chemotherapy. Based on the median post-adjuvant chemotherapy SUA level (350.48 µmol/l), patients were stratified into high (SUA >350 µmol/l) and low (SUA ≤350 µmol/l) groups. Survival outcomes were compared using Kaplan-Meier analysis and log-rank tests. Cox proportional hazards models were employed to identify independent prognostic factors. Changes in SUA levels over time were assessed using repeated-measures ANOVA. The high SUA group demonstrated improved 3-year overall survival (OS; P=0.037), progression-free survival (PFS; P<0.001), and distant metastasis-free survival (DMFS; P=0.001) compared with the low SUA group. No significant difference in locoregional relapse-free survival (P=0.41) was observed. Post-adjuvant chemotherapy SUA levels were an independent prognostic factor for OS, PFS and DMFS. Repeated-measures ANOVA showed a significant reduction in SUA levels post-IMRT compared with baseline, post-induction chemotherapy, and post-adjuvant chemotherapy (all P<0.001). In conclusion, elevated post-adjuvant chemotherapy SUA levels are associated with improved survival outcomes in patients with advanced-stage NPC. IMRT induces a transient decrease in SUA levels. These findings suggested that SUA levels may serve as a valuable prognostic biomarker for NPC.

评估鼻咽癌(NPC)患者血清尿酸(SUA)水平与诱导化疗、调强放疗(IMRT)和辅助化疗综合方案治疗的预后之间的关系。回顾性分析2017 - 2021年在南昌大学第二附属医院治疗的182例鼻咽癌患者。在治疗前、诱导化疗后、imrt后和辅助化疗后四个时间点记录SUA水平。根据辅助化疗后中位SUA水平(350.48µmol/l),将患者分为高(SUA≤350µmol/l)组和低(SUA≤350µmol/l)组。生存结果采用Kaplan-Meier分析和log-rank检验进行比较。采用Cox比例风险模型确定独立预后因素。使用重复测量方差分析评估SUA水平随时间的变化。高SUA组3年总生存期(OS, P=0.037)、无进展生存期(PFS, P=0.037)明显改善
{"title":"Prognostic value of serum uric acid levels following radiotherapy and chemotherapy in nasopharyngeal carcinoma.","authors":"Xianming He, Qiwei Luo, Yuhao Ding, Jianwu Ding, Ronghuan Hu, Jia-Li Hu, Lei Tao, Jianze Zhang, Zhenxing Huang, Xiaoqiang Chen, Jiayin Wu, Su Deng, Shubin Luo, Lei Zeng, Mengmeng Liu","doi":"10.3892/mco.2026.2924","DOIUrl":"https://doi.org/10.3892/mco.2026.2924","url":null,"abstract":"<p><p>To evaluate the association between serum uric acid (SUA) levels and prognosis in patients with nasopharyngeal carcinoma (NPC) treated with a comprehensive regimen of induction chemotherapy, intensity-modulated radiation therapy (IMRT), and adjuvant chemotherapy. A total of 182 patients with NPC treated at the Second Affiliated Hospital of Nanchang University between 2017 and 2021 were retrospectively analyzed. SUA levels were recorded at four time points: Pre-treatment, post-induction chemotherapy, post-IMRT and post-adjuvant chemotherapy. Based on the median post-adjuvant chemotherapy SUA level (350.48 µmol/l), patients were stratified into high (SUA >350 µmol/l) and low (SUA ≤350 µmol/l) groups. Survival outcomes were compared using Kaplan-Meier analysis and log-rank tests. Cox proportional hazards models were employed to identify independent prognostic factors. Changes in SUA levels over time were assessed using repeated-measures ANOVA. The high SUA group demonstrated improved 3-year overall survival (OS; P=0.037), progression-free survival (PFS; P<0.001), and distant metastasis-free survival (DMFS; P=0.001) compared with the low SUA group. No significant difference in locoregional relapse-free survival (P=0.41) was observed. Post-adjuvant chemotherapy SUA levels were an independent prognostic factor for OS, PFS and DMFS. Repeated-measures ANOVA showed a significant reduction in SUA levels post-IMRT compared with baseline, post-induction chemotherapy, and post-adjuvant chemotherapy (all P<0.001). In conclusion, elevated post-adjuvant chemotherapy SUA levels are associated with improved survival outcomes in patients with advanced-stage NPC. IMRT induces a transient decrease in SUA levels. These findings suggested that SUA levels may serve as a valuable prognostic biomarker for NPC.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 2","pages":"15"},"PeriodicalIF":1.4,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduction of seroma by pectoralis fascia dissection using an energy device in total mastectomy for breast cancer: An observational study. 在乳腺癌全乳切除术中使用能量装置胸肌筋膜剥离术减少血肿:一项观察性研究。
IF 1.4 Q4 ONCOLOGY Pub Date : 2026-01-08 eCollection Date: 2026-02-01 DOI: 10.3892/mco.2026.2923
Hiroaki Shima, Yuta Kondo, Takashi Nakamura, Daisuke Kyuno, Noriko Nishikawa, Satoko Uno, Ai Noda, Kiminori Sato, Asaka Wada, Toru Mizuguchi

Seroma formation is one of the unresolved complications of breast cancer surgery. The use of energy devices (EDs) can improve breast cancer surgery outcomes. Dissection of the pectoralis fascia is an important process in total mastectomy, which involves a wide area of the posterior wall of the mammary glands. The current study investigated whether using EDs for this process could lead to a reduction in seroma formation or potentially reduce other complications. In the present observational study, the use of an ED for pectoralis fascia dissection was compared with conventional electrocautery. The main outcomes were the total amount of drainage (total AD), amount of drainage per day and adverse events (AEs) after propensity score matching (PSM). in addition, a univariate analysis of AE occurrence was performed. Overall, 41 and 117 patients were included in the ED and control groups, respectively. PSM was performed for three covariates: Presence or absence of axillary dissection, preoperative chemotherapy and body mass index >25 kg/m2. Compared with those in the control group, the total AD post-PSM in the ED group did not decrease (P=0.1778), whereas the amount of drainage per day was markedly decreased on postoperative day 8 in the ED group. In the univariate analysis, only the use of ED was associated with a reduction in AEs requiring intervention; other factors showed no significant association. The frequency of AEs requiring intervention was significantly lower in the ED group than that in the control group post-PSM (P=0.0372). Notably, seroma accounted for most AEs. The results of the present study suggested that pectoralis fascia dissection using an ED may reduce fluid drainage and the incidence of AEs. This simple modification suggests the possibility of improving surgical techniques and is expected to contribute to favorable surgical outcomes.

血清肿形成是乳腺癌手术中尚未解决的并发症之一。使用能量装置(EDs)可以改善乳腺癌手术的效果。胸肌筋膜的剥离是全乳切除术的一个重要过程,它涉及到乳腺后壁的广泛区域。目前的研究调查了在这一过程中使用EDs是否可以减少血肿的形成或潜在地减少其他并发症。在目前的观察性研究中,使用ED进行胸肌筋膜剥离与传统的电疗进行比较。主要结果为总引流量(total AD)、每日引流量和倾向评分匹配(PSM)后的不良事件(ae)。此外,还进行了AE发生的单变量分析。总体而言,ED组和对照组分别有41例和117例患者。三个协变量:是否有腋窝清扫、术前化疗和体重指数bbb25 kg/m2进行PSM。与对照组相比,ED组psm后总AD未减少(P=0.1778),而ED组术后第8天每天引流量明显减少。在单变量分析中,只有ED的使用与需要干预的不良事件的减少有关;其他因素无显著相关性。psm后,ED组需要干预的不良事件发生频率明显低于对照组(P=0.0372)。值得注意的是,血清瘤占ae的大多数。本研究的结果表明,使用ED进行胸肌筋膜剥离可以减少液体引流和ae的发生率。这种简单的修改提示了改进手术技术的可能性,并有望促进良好的手术结果。
{"title":"Reduction of seroma by pectoralis fascia dissection using an energy device in total mastectomy for breast cancer: An observational study.","authors":"Hiroaki Shima, Yuta Kondo, Takashi Nakamura, Daisuke Kyuno, Noriko Nishikawa, Satoko Uno, Ai Noda, Kiminori Sato, Asaka Wada, Toru Mizuguchi","doi":"10.3892/mco.2026.2923","DOIUrl":"https://doi.org/10.3892/mco.2026.2923","url":null,"abstract":"<p><p>Seroma formation is one of the unresolved complications of breast cancer surgery. The use of energy devices (EDs) can improve breast cancer surgery outcomes. Dissection of the pectoralis fascia is an important process in total mastectomy, which involves a wide area of the posterior wall of the mammary glands. The current study investigated whether using EDs for this process could lead to a reduction in seroma formation or potentially reduce other complications. In the present observational study, the use of an ED for pectoralis fascia dissection was compared with conventional electrocautery. The main outcomes were the total amount of drainage (total AD), amount of drainage per day and adverse events (AEs) after propensity score matching (PSM). in addition, a univariate analysis of AE occurrence was performed. Overall, 41 and 117 patients were included in the ED and control groups, respectively. PSM was performed for three covariates: Presence or absence of axillary dissection, preoperative chemotherapy and body mass index >25 kg/m<sup>2</sup>. Compared with those in the control group, the total AD post-PSM in the ED group did not decrease (P<i>=</i>0.1778), whereas the amount of drainage per day was markedly decreased on postoperative day 8 in the ED group. In the univariate analysis, only the use of ED was associated with a reduction in AEs requiring intervention; other factors showed no significant association. The frequency of AEs requiring intervention was significantly lower in the ED group than that in the control group post-PSM (P=0.0372). Notably, seroma accounted for most AEs. The results of the present study suggested that pectoralis fascia dissection using an ED may reduce fluid drainage and the incidence of AEs. This simple modification suggests the possibility of improving surgical techniques and is expected to contribute to favorable surgical outcomes.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 2","pages":"14"},"PeriodicalIF":1.4,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12836455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146093075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of ramucirumab and subsequent nivolumab therapy in patients with advanced gastric cancer: A retrospective study 晚期胃癌患者接受雷莫芦单抗和随后的尼夫单抗治疗的疗效:回顾性研究
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-01-09 DOI: 10.3892/mco.2024.2715
Masaaki Saito, Koichi Suzuki, S. Tamaki, Yasuaki Kimura, I. Abe, Y. Endo, F. Watanabe, T. Rikiyama
{"title":"Efficacy of ramucirumab and subsequent nivolumab therapy in patients with advanced gastric cancer: A retrospective study","authors":"Masaaki Saito, Koichi Suzuki, S. Tamaki, Yasuaki Kimura, I. Abe, Y. Endo, F. Watanabe, T. Rikiyama","doi":"10.3892/mco.2024.2715","DOIUrl":"https://doi.org/10.3892/mco.2024.2715","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"42 33","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139442240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metastatic splenic angiosarcoma presenting with anemia and bone marrow fibrosis mimicking primary myelofibrosis: A case report and literature review 转移性脾血管肉瘤伴有贫血和骨髓纤维化,酷似原发性骨髓纤维化:病例报告和文献综述
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-01-04 DOI: 10.3892/mco.2024.2714
Meiqing Wu, Zhongqing Li, Lin Luo, Weihua Zhao, Jun Luo
{"title":"Metastatic splenic angiosarcoma presenting with anemia and bone marrow fibrosis mimicking primary myelofibrosis: A case report and literature review","authors":"Meiqing Wu, Zhongqing Li, Lin Luo, Weihua Zhao, Jun Luo","doi":"10.3892/mco.2024.2714","DOIUrl":"https://doi.org/10.3892/mco.2024.2714","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 2","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139387105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio 利用血液参数和比值对接受艾瑞布林治疗的转移性乳腺癌进行综合预后预测
IF 1.2 Q4 ONCOLOGY Pub Date : 2024-01-03 DOI: 10.3892/mco.2024.2713
H. Shimada, A. Fujimoto, Kazuo Matsuura, Shunsuke Kohyama, Asami Nukui, Y. Ichinose, Aya Asano, Masahiro Ohara, Hiroshi Ishiguro, Akihiko Osaki, Toshiaki Saeki
{"title":"Comprehensive prognostic prediction of metastatic breast cancer treated with eribulin using blood‑based parameters and ratio","authors":"H. Shimada, A. Fujimoto, Kazuo Matsuura, Shunsuke Kohyama, Asami Nukui, Y. Ichinose, Aya Asano, Masahiro Ohara, Hiroshi Ishiguro, Akihiko Osaki, Toshiaki Saeki","doi":"10.3892/mco.2024.2713","DOIUrl":"https://doi.org/10.3892/mco.2024.2713","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"125 17","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139387717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miR‑146a‑5p and miR‑191‑5p as novel diagnostic marker candidates for ovarian clear cell carcinoma miR-146a-5p 和 miR-191-5p 作为卵巢透明细胞癌的新型候选诊断标记物
IF 1.2 Q4 ONCOLOGY Pub Date : 2023-12-28 DOI: 10.3892/mco.2023.2712
Shigeatsu Takamizawa, J. Kojima, Tomohiro Umezu, Masahiko Kuroda, Shigehiro Hayashi, Takenori Maruta, A. Okamoto, Hirotaka Nishi
{"title":"miR‑146a‑5p and miR‑191‑5p as novel diagnostic marker candidates for ovarian clear cell carcinoma","authors":"Shigeatsu Takamizawa, J. Kojima, Tomohiro Umezu, Masahiko Kuroda, Shigehiro Hayashi, Takenori Maruta, A. Okamoto, Hirotaka Nishi","doi":"10.3892/mco.2023.2712","DOIUrl":"https://doi.org/10.3892/mco.2023.2712","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"24 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139149804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Albumin‑bilirubin grade is an independent prognostic factor for small lung cell cancer 白蛋白-胆红素分级是小肺细胞癌的独立预后因素
IF 1.2 Q4 ONCOLOGY Pub Date : 2023-12-15 DOI: 10.3892/mco.2023.2710
Shicheng Liu, Qingtao Zhao, Zengming Wang, Bin Zhao, Xiaopeng Zhang
{"title":"Albumin‑bilirubin grade is an independent prognostic factor for small lung cell cancer","authors":"Shicheng Liu, Qingtao Zhao, Zengming Wang, Bin Zhao, Xiaopeng Zhang","doi":"10.3892/mco.2023.2710","DOIUrl":"https://doi.org/10.3892/mco.2023.2710","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"104 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138998583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rare coexistence of multiple osteochondromas and solitary osteoid osteoma: A case report 罕见的多发性骨软骨瘤和单发骨样骨瘤并存:病例报告
IF 1.2 Q4 ONCOLOGY Pub Date : 2023-12-15 DOI: 10.3892/mco.2023.2711
Ryo Katsuki, Hiromichi Oshiro, Yusuke Aoki, Kohei Mizuta, Y. Tome, Kotaro Nishida
{"title":"Rare coexistence of multiple osteochondromas and solitary osteoid osteoma: A case report","authors":"Ryo Katsuki, Hiromichi Oshiro, Yusuke Aoki, Kohei Mizuta, Y. Tome, Kotaro Nishida","doi":"10.3892/mco.2023.2711","DOIUrl":"https://doi.org/10.3892/mco.2023.2711","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"32 2","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139000157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
lncRNAs are potential prognostic markers in patients with nasopharyngeal carcinoma in China: A systematic review and meta‑analysis lncRNAs是中国鼻咽癌患者潜在的预后标志物:系统综述和荟萃分析
IF 1.2 Q4 ONCOLOGY Pub Date : 2023-12-14 DOI: 10.3892/mco.2023.2709
Peng Yu, Jiemei Ye, Shujian Zhao, Yonglin Cai
{"title":"lncRNAs are potential prognostic markers in patients with nasopharyngeal carcinoma in China: A systematic review and meta‑analysis","authors":"Peng Yu, Jiemei Ye, Shujian Zhao, Yonglin Cai","doi":"10.3892/mco.2023.2709","DOIUrl":"https://doi.org/10.3892/mco.2023.2709","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"572 1","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138974077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between platelet‑to‑lymphocyte ratio and serum prostate specific antigen 血小板与淋巴细胞比率与血清前列腺特异性抗原之间的关系
IF 1.2 Q4 ONCOLOGY Pub Date : 2023-12-12 DOI: 10.3892/mco.2023.2708
Bowen Hu, Minbo Yan, Shuchang Huang, Hui Liang, Wenfei Lian
{"title":"Association between platelet‑to‑lymphocyte ratio and serum prostate specific antigen","authors":"Bowen Hu, Minbo Yan, Shuchang Huang, Hui Liang, Wenfei Lian","doi":"10.3892/mco.2023.2708","DOIUrl":"https://doi.org/10.3892/mco.2023.2708","url":null,"abstract":"","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"38 5","pages":""},"PeriodicalIF":1.2,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139007872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Molecular and clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1